COVID-19 Tragic Pandemic: Concerns over Unintentional "Directed Accelerated Evolution" of Novel Coronavirus (SARS-CoV-2) and Introducing a Modified Treatment Method for ARDS.
Coronavirus
Directed Evolution
Radiation Dosage
Respiratory Distress Syndrome
Selective Pressure
X-Rays
Journal
Journal of biomedical physics & engineering
ISSN: 2251-7200
Titre abrégé: J Biomed Phys Eng
Pays: Iran
ID NLM: 101589641
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
17
03
2020
accepted:
23
03
2020
entrez:
28
4
2020
pubmed:
28
4
2020
medline:
28
4
2020
Statut:
epublish
Résumé
Global health authorities are trying to work out the current status of the novel coronavirus (COVID-19) outbreak and explore methods to reduce the rate of its transmission to healthy individuals. In this viewpoint we provide insights concerning how health care professionals can unintentionally shift the novel coronavirus type to more drug-resistant forms. It is worth noting that viruses usually have different sensitivities to physical and chemical damaging agents such antiviral drugs, UV and heat ranging from extremely sensitive (ES) to extremely resistant (ER) based on a bell-shaped curve. Given this consideration, the widespread infection of people with such ER viruses would be a real disaster. Here, we introduce a modified treatment method for COVID-19-associated pneumonia. In this proposed method, COVID-19 patients will receive a single dose of 100, 180 or 250 mSv X-ray radiation that is less than the maximum annual radiation dose of the residents of high background radiation areas of Ramsar that is up to 260 mSv. In contrast with antiviral drugs, a single dose of either 100, 180 or 250 mSv of low LET X-rays cannot exert a significant selective pressure on the novel coronavirus (SARS-CoV-2) and hence does not lead to directed accelerated evolution of these viruses. Moreover, Low Dose Radiation (LDR) has the capacity of modulating excessive inflammatory responses, regulating lymphocyte counts, and controling bacterial co-infections in patients with COVID-19.
Identifiants
pubmed: 32337192
doi: 10.31661/jbpe.v0i0.2003-1085
pii: JBPE-10-2
pmc: PMC7166223
doi:
Types de publication
Journal Article
Langues
eng
Pagination
241-246Informations de copyright
Copyright: © Journal of Biomedical Physics and Engineering.
Déclaration de conflit d'intérêts
Conflict of Interest: None
Références
Lancet Public Health. 2020 Apr;5(4):e186-e187
pubmed: 32171054
J Med Virol. 2020 Mar 14;:
pubmed: 32170865
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
Future Oncol. 2016 Jan;12(2):239-56
pubmed: 26621553
J Med Virol. 2020 Feb 25;:
pubmed: 32096567
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):170-172
pubmed: 32164080
Int J Surg. 2020 Apr;76:71-76
pubmed: 32112977
J Immunol Res. 2018 Jun 3;2018:2856518
pubmed: 29967799
Cancer Biother Radiopharm. 2014 Dec;29(10):428-34
pubmed: 25402754
Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9
pubmed: 32105090
J Pharm Anal. 2020 Mar 5;:
pubmed: 32282863
Indian J Pediatr. 2020 Apr;87(4):281-286
pubmed: 32166607
Ther Adv Med Oncol. 2018 Jan 18;10:1758834017742575
pubmed: 29383033
Front Oncol. 2012 Sep 25;2:120
pubmed: 23057008
Lancet Infect Dis. 2020 Mar 11;:
pubmed: 32171059